isirv
antivir
group
confer
entitl
sever
influenza
burden
pathogenesi
manag
organ
conjunct
nation
institut
hygien
epidemiolog
nihe
held
hanoi
vietnam
octob
aftermath
pandem
continu
threat
avian
infect
emerg
respiratori
viru
infect
middl
east
respiratori
syndrom
coronaviru
purpos
meet
address
mani
gap
understand
pathogenesi
clinic
manag
sever
influenza
respiratori
viru
infect
meet
compris
invit
lectur
number
subject
detail
summari
supplement
oral
poster
abstract
present
new
data
follow
summari
highlight
key
point
made
meet
reader
refer
nine
review
articl
supplement
comprehens
coverag
particular
topic
scene
set
review
conclus
previou
isirv
meet
entitl
incid
sever
impact
season
pandem
influenza
septemb
keynot
present
asian
perspect
epidemiolog
impact
sever
influenza
sever
acut
respiratori
infect
gener
emphas
import
strengthen
variou
aspect
influenza
surveil
increas
surveil
variou
countri
asia
continu
provid
inform
factor
affect
epidemiolog
demograph
season
influenza
respiratori
infect
well
role
region
play
global
dynam
influenza
evolut
epidemiolog
overview
use
influenza
vaccin
combat
season
pandem
influenza
emphas
difficulti
implement
effect
control
strategi
consist
vaccin
polici
region
see
l
jen
issu
one
core
function
world
health
organ
develop
recommend
guidelin
manag
influenza
infect
particular
sever
diseas
respons
human
case
avian
influenza
influenza
pandem
seri
emerg
interim
guidelin
publish
recent
consolid
incorpor
extens
review
exist
literatur
produc
comprehens
standard
guidelin
clinic
manag
sever
influenza
diseas
prepar
futur
emerg
broad
scope
encompass
follow
treatment
sever
influenza
exampl
viral
pneumonia
ard
multipl
organ
failur
septic
shock
pharmacolog
intervent
treatment
includ
drug
drug
adjunct
therapi
clinic
intervent
mechan
ventil
oxygen
fluid
manag
prevent
sever
influenza
patient
higher
risk
progress
sever
diseas
facilit
collect
knowledg
need
address
key
question
associ
prevent
treatment
full
spectrum
respiratori
viral
infect
also
spearhead
public
health
research
agenda
influenza
call
battl
respiratori
virus
brave
associ
research
agenda
recent
post
websit
http
wwwwhointinfluenzapatientcareclinicalbraveen
pathogenesi
sever
influenza
affect
variat
viru
host
factor
interact
one
anoth
emerg
data
shed
light
complex
combin
viru
factor
eg
genet
constel
virul
receptor
specif
tropism
host
factor
eg
underli
immunosuppress
genet
suscept
interact
eg
innat
receptor
tlr
rlr
nlr
inflammasom
damp
interferon
cytokin
adapt
respons
involv
complex
pose
particular
challeng
physician
manag
sever
diseas
observ
data
mortal
attribut
season
pandem
influenza
sever
acut
respiratori
syndrom
children
year
age
usual
significantli
lower
older
contrast
season
influenza
pandem
associ
lower
mortal
elderli
part
explain
higher
preval
antibodi
older
howev
serum
antibodi
direct
influenza
may
predispos
patient
risk
sever
diseas
exampl
higher
incid
pulmonari
immun
complex
deposit
observ
patient
sever
presenc
immun
also
associ
blunt
sever
season
influenza
pregnant
women
higher
rate
hospit
death
result
infect
pandem
howev
contrast
countri
matern
mortal
among
pregnant
japanes
women
attribut
pandem
part
aggress
use
antivir
agent
prophylaxi
obes
also
recent
recogn
risk
factor
sever
influenza
includ
increas
risk
complic
two
studi
report
shift
older
age
group
sever
influenza
due
viru
season
one
studi
patient
beij
also
observ
pneumonia
seriou
patient
infect
patient
season
infect
studi
england
conclud
increas
impact
critic
care
reflect
increas
transmiss
associ
lower
temperatur
secondari
bacteri
infect
innat
immun
system
play
key
role
earli
influenza
infect
cytokineimmun
dysregul
import
diseas
pathogenesi
patient
appear
differenti
express
tlr
monocyt
dendrit
cell
higher
express
tlr
dendrit
cell
tlr
monocyt
lower
level
tlr
monocyt
furthermor
neg
correl
express
tlr
monocyt
dendrit
cell
viru
load
contradistinct
higher
concentr
cytokin
interleukin
il
associ
higher
viru
load
wors
clinic
symptom
longer
length
hospit
higher
risk
icu
admiss
season
pandem
extens
studi
caus
sever
influenza
pandem
includ
patient
enrol
mechan
sever
acut
influenza
consortium
mosaic
uk
identifi
minor
variant
snp
gene
encod
innat
restrict
factor
transmembran
protein
appear
preval
among
patient
requir
hospit
admiss
secondari
increas
viru
replic
andor
alter
cytokin
hyperactiv
proinflammatori
suppress
adapt
immun
cytokin
respons
pattern
found
patient
sever
pneumonia
differ
seen
patient
season
studi
previous
healthi
adult
admit
nation
hospit
tropic
diseas
vietnam
infect
show
sever
symptom
develop
patient
associ
transient
nk
cell
phenotyp
chang
mild
influenza
patient
consist
rapidli
resolv
memori
respons
wherea
sever
influenza
activ
either
delay
excess
recruit
effector
cell
lung
appear
impair
cytokin
regul
complex
cytoplasm
protein
scaffold
known
ice
gene
upregul
follow
infect
highli
pathogen
avian
influenza
hpai
viru
chicken
indic
strong
inflammasom
respons
associ
sever
mortal
modul
pathway
may
repres
anoth
option
mitig
advers
consequ
hpai
bacteri
infect
common
complic
influenza
contribut
sever
burden
ill
j
deng
issu
innat
immun
respons
critic
control
influenza
may
also
influenc
risk
secondari
bacteri
innat
respons
link
increas
risk
secondari
bacteri
infect
tlr
agonist
synthet
compound
contain
tlr
agonist
administ
lung
mice
result
tlr
character
induct
neutrophil
macrophag
nk
cell
lymphocyt
inflammatori
cytokin
protect
mice
virul
infect
reduc
viru
burden
follow
challeng
virus
well
respiratori
syncyti
furthermor
prophylaxi
prevent
lethal
associ
secondari
pneumonia
infect
host
specif
viru
contribut
diseas
pathogenesi
viru
appear
better
abl
replic
lower
airway
may
partli
explain
higher
incid
virul
virus
multigen
properti
result
complex
interplay
variou
viru
factor
host
compon
exampl
influenza
viral
polymeras
complex
pa
np
viru
rna
shown
associ
network
human
host
protein
function
genom
rnai
approach
allow
studi
host
factor
regul
viru
rna
synthesi
induct
innat
immun
respons
adapt
human
cell
number
cellular
protein
differ
activ
shown
modul
polymeras
activ
protein
includ
rna
helicas
also
govern
polymeras
activ
effici
infect
human
chicken
cell
accord
determin
residu
thu
network
viru
protein
interact
part
control
adapt
replic
pathogen
virus
human
would
also
potenti
target
therapeut
intervent
addit
receptor
bind
proteas
cleavag
properti
ha
ph
activ
ha
determin
virul
duck
chicken
may
influenc
interspeci
transmiss
compar
studi
mice
show
viru
fusion
ph
replic
effici
substitut
destabil
ha
protein
activ
ph
attenu
viru
replic
mice
wherea
stabil
substitut
lower
activ
ph
ph
unit
result
greater
viru
replic
lung
mice
increas
weight
loss
mortal
addit
enhanc
replic
upper
respiratori
tract
infect
mice
find
could
help
optim
vaccin
better
replic
thu
immun
nasal
caviti
identifi
novel
target
antivir
drug
develop
identif
agent
respons
respiratori
diseas
particular
pneumonia
continu
present
physician
seriou
challeng
despit
rapid
growth
molecular
diagnost
rapid
particular
nucleic
test
larg
replac
method
qpcr
microarray
particularli
adept
multiplex
screen
wide
varieti
organ
may
limit
mutat
emerg
evolut
emerg
novel
variant
one
end
spectrum
complex
pathchip
system
amplifi
virus
bacteria
whatev
genet
divers
automat
detect
presenc
viru
bacteria
genom
singl
test
clinic
sampl
describ
one
trial
sampl
compar
perform
multiplex
respiratori
diagnosi
platform
cell
cultur
chip
achiev
averag
specif
averag
sensit
group
virus
averag
neg
predict
valu
wide
rang
test
also
applic
molecular
epidemiolog
viru
discoveri
end
spectrum
need
simpl
highli
sensit
method
rapid
detect
human
infect
assay
develop
combin
revers
transcriptas
rt
isotherm
dna
amplif
reaction
singl
step
therebi
avoid
rna
extract
pcr
provid
practic
tool
highli
sensit
lower
limit
detect
copi
viru
rna
season
virus
incorpor
hybrid
sensit
fluoresc
primer
high
ratio
facilit
visual
detect
aetiolog
studi
pneumonia
beij
patient
mean
age
rang
year
screen
use
variou
test
wide
rang
bacteria
respiratori
virus
percent
least
one
pathogen
detect
pneumonia
influenza
viru
bacteria
human
rhinoviru
adenoviru
frequent
associ
higher
risk
mortal
pneumonia
adenoviru
seen
frequent
younger
patient
influenza
bacteri
pneumonia
common
among
older
patient
empir
treatment
take
account
local
epidemiolog
data
small
number
studi
describ
antivir
effect
either
observ
studi
patient
japan
given
one
four
avail
neuraminidas
inhibitor
nai
oseltamivir
zanamivir
laninamivir
peramivir
combin
therapi
studi
use
anim
model
studi
paediatr
patient
treat
one
four
nai
show
peramivir
treatment
achiev
fastest
allevi
fever
compar
three
nai
howev
four
patient
receiv
peramivir
comparison
effect
oseltamivir
zanamivir
patient
show
similar
time
allevi
symptom
separ
studi
singl
mg
intraven
infus
peramivir
also
shown
effect
nai
reduc
durat
fever
patient
infect
virus
effect
four
nai
lower
treatment
influenza
b
influenza
viru
infect
although
treatment
peramivir
zanamivir
result
faster
allevi
fever
influenza
patient
achiev
oseltamivir
laninamivir
concern
patient
still
shed
influenza
b
viru
complet
day
cours
nai
treatment
demonstr
need
new
treatment
option
influenza
b
particularli
sever
ill
patient
benefit
combin
antivir
therapi
review
studi
shown
compar
monotherapi
combin
certain
antivir
reduc
likelihood
select
resist
strain
number
secondari
case
effect
combin
treatment
two
differ
nai
shown
antagonist
synerg
drug
target
differ
protein
stage
replic
demonstr
although
clinic
studi
necessari
number
anim
studi
investig
antivir
effect
report
effect
peramivir
season
variant
contain
na
mutat
investig
mice
despit
demonstr
reduc
sensit
vitro
peramivir
effect
prevent
mortal
mice
oseltamivir
treatment
effect
g
boivin
issu
whether
appli
virus
mutat
requir
studi
anoth
mous
studi
demonstr
benefit
treatment
combin
polymeras
inhibitor
favipiravir
either
oseltamivir
laninamivir
compar
monotherapi
follow
infect
mice
antivir
treatment
durat
rang
day
week
combin
favipiravir
plu
laninamivir
show
superior
effect
compar
favipiravir
plu
oseltamivir
drug
given
alon
separ
studi
laninamivir
monotherapi
shown
effect
delay
prevent
contact
transmiss
guinea
pig
model
lack
mortal
among
pregnant
women
japan
pandem
appear
due
aggress
use
antivir
vaccin
advic
japan
societi
obstetr
gynecolog
jsog
includ
follow
earli
visit
gener
practition
febril
prompt
use
antivir
activ
use
antivir
prophylaxi
close
contact
infect
person
vaccin
pandem
viru
vaccin
becam
avail
data
suggest
antivir
medic
given
prophylaxi
pregnant
women
pregnant
women
vaccin
within
month
avail
vaccin
appar
consequ
rate
infect
pandem
viru
lower
among
pregnant
women
gener
popul
versu
outcom
women
sever
influenza
low
compar
data
report
frequenc
resist
nai
treat
patient
sampl
collect
via
human
anim
surveil
programm
frequenc
resist
patient
determin
prospect
multicentr
studi
call
iri
coordin
roch
sinc
analysi
virus
patient
undergo
oseltamivir
treatment
reveal
approxim
paediatr
patient
age
year
shed
viru
na
mutat
frequenc
resist
significantli
lower
older
age
group
approxim
furthermor
frequenc
case
shed
resist
viru
higher
previou
year
despit
similar
number
patient
enrol
period
viral
shed
prolong
patient
shed
variant
infect
viru
demonstr
reduc
effect
oseltamivir
variant
strain
infect
variant
detect
two
dutch
travel
return
vacat
spain
treat
strain
also
contain
three
potenti
permiss
na
mutat
suggest
facilit
spread
resist
viru
commun
cluster
australia
new
insight
mechan
oseltamivir
resist
confer
substitut
na
virus
provid
crystallograph
analysi
na
demonstr
substitut
caus
narrow
region
enzymat
site
result
greater
reduct
oseltamivir
zanamivir
mice
continu
infect
virus
oseltamivir
treatment
select
variant
na
mutat
laninamivir
treatment
select
variant
na
mutat
virus
reduc
suscept
favipiravir
detect
follow
treatment
polymeras
inhibitor
variat
nai
suscept
among
virus
collect
wild
bird
poultri
asia
describ
notabl
lower
oseltamivir
sensit
indonesian
clade
virus
clade
virus
substitut
residu
na
detect
number
strain
indonesia
vietnam
confer
reduct
oseltamivir
strain
isol
duck
vietnam
found
mutat
na
consequ
significantli
reduc
oseltamivir
suscept
assist
coordin
report
nai
suscept
data
deriv
use
na
inhibit
assay
set
criteria
propos
expert
committe
base
fold
increas
compar
virus
normal
inhibit
normal
reduc
highli
reduc
suscept
influenza
greater
fivefold
fivefold
increas
respect
influenza
b
addit
tool
assist
laboratori
conduct
nai
suscept
test
discuss
includ
panel
refer
virus
http
wwwisirvorgsiteindexphpreferencepanel
softwar
jaspr
determin
valu
cdc
number
studi
report
effect
nai
resist
mutat
viru
replic
andor
transmiss
includ
permiss
mutat
play
role
offset
deleteri
effect
resist
mutat
two
na
mutat
previous
report
confer
zanamivir
resist
investig
use
revers
virus
better
understand
effect
vitro
vivo
variant
exhibit
reduc
cell
surfac
na
activ
viru
replic
vitro
reduc
viru
replic
mice
reduc
viru
replic
transmiss
ferret
revers
variant
wild
type
ferret
demonstr
lack
fit
variant
two
permiss
substitut
residu
na
shown
play
role
enabl
season
virus
acquir
mutat
without
compromis
fit
investig
context
variant
substitut
residu
increas
affin
substrat
virus
effect
chang
residu
vari
depend
amino
acid
substitut
na
sequenc
three
potenti
permiss
substitut
na
cluster
virus
detect
australia
investig
ferret
model
effect
viru
replic
transmiss
two
substitut
current
present
major
circul
virus
shown
improv
fit
variant
ferret
therebi
demonstr
potenti
variant
emerg
similar
manner
seen
season
virus
number
novel
agent
either
develop
undergo
clinic
trial
describ
nitazoxanid
thiazolid
compound
approv
treatment
cryptosporidium
giardia
shown
inhibit
vitro
replic
broad
rang
virus
includ
influenza
parainfluenza
virus
mechan
action
attribut
stimul
innat
immun
via
pathway
well
direct
effect
inhibit
ha
matur
viru
phase
iiiii
clinic
trial
demonstr
mg
dose
bid
day
significantli
reduc
symptom
durat
viru
load
compar
placebo
minim
advers
event
report
combin
nitazoxanid
oseltamivir
synergist
inhibit
replic
influenza
virus
vitro
phase
iii
studi
combin
plan
barda
recent
approv
million
support
develop
nitazoxanid
manag
influenza
studi
mode
action
polymeras
inhibitor
favipiravir
describ
serial
passag
vitro
influenza
virus
presenc
increas
favipiravir
concentr
result
reduc
viru
polymeras
fidel
consequ
increas
frequenc
transvers
mutat
replic
led
lack
viabl
phase
iii
clinic
trial
favipiravir
treat
uncompl
influenza
recent
complet
japan
plan
countri
report
prior
pandem
suggest
intraven
immunoglobulin
ivig
may
improv
clinic
outcom
sever
impact
may
result
neutral
either
homolog
heterolog
reactiv
infecti
viru
modul
immun
respons
blunt
cytokin
storm
seen
patient
two
ferret
model
util
investig
role
ivig
infect
singl
dose
ivig
harvest
prior
given
time
challeng
prevent
signific
viru
replic
lung
upper
respiratori
tract
ferret
singl
dose
ivig
prevent
mortal
signific
morbid
follow
challeng
lethal
dose
viru
level
viru
replic
lung
correl
dose
ivig
differ
studi
polyclon
immunoglobulin
deriv
plasma
hors
immun
inactiv
viru
shown
good
vitro
differ
clade
virus
fulli
protect
mice
particular
interest
potenti
therapeut
use
monoclon
antibodi
mab
target
conserv
region
ha
demonstr
effect
prophylaxi
treatment
mice
rang
differ
human
mab
target
stalk
region
ha
found
effect
treat
season
influenza
b
highli
pathogen
infect
mab
bind
stalk
group
outperform
oseltamivir
given
mice
day
post
infect
versu
mortal
respect
shown
still
effect
given
day
effect
use
prophylact
therapeut
protect
ferret
lethal
mab
bind
stalk
group
prevent
infect
effect
treat
mice
day
infect
recent
three
human
mab
influenza
b
two
bound
epitop
head
ha
influenza
b
virus
bind
conserv
epitop
stem
protect
mice
lethal
challeng
either
influenza
b
clinic
trial
antibodi
commenc
proof
concept
studi
therapi
sever
influenza
guid
diagnost
expect
follow
shortli
thereaft
mab
design
use
atom
interact
network
analysi
also
exploit
conserv
region
stem
ha
neutral
group
influenza
virus
studi
mice
suggest
prophylaxi
treatment
regimen
prevent
weight
loss
result
reduct
viru
titr
experiment
exposur
subtyp
phase
safeti
studi
proof
concept
studi
util
human
challeng
model
current
plan
hope
start
phase
ii
studi
high
risk
eg
transplant
recipi
nurs
home
resid
sever
ill
hospit
adult
exploit
vital
role
host
protein
play
influenza
replic
may
offer
new
therapeut
target
abil
decreas
viru
replic
modul
express
host
protein
involv
cellular
pathway
endocytosi
downregul
protein
coat
protein
complex
sirna
copa
brefeldin
achiev
modest
reduct
infect
human
cell
without
associ
cytotox
demonstr
potenti
influenza
replic
reduc
inhibit
host
protein
separ
studi
use
cdna
microarray
long
rna
microarray
analys
two
gene
cell
shown
differenti
express
follow
influenza
infect
associ
transport
na
infect
cell
provid
possibl
futur
antivir
target
relat
discuss
futur
research
need
emphas
conduct
public
health
clinic
research
set
epidem
novel
infecti
diseas
vital
except
challeng
studi
conduct
oxford
univers
clinic
research
unit
oucru
ho
chi
minh
citi
viet
nam
three
hospit
viet
nam
experi
epidem
interview
focu
group
discuss
involv
peopl
repres
differ
constitu
health
system
research
staff
patient
particip
review
research
project
infecti
diseas
seven
main
theme
emerg
concern
divid
line
public
health
need
medic
practic
research
ii
vulner
research
particip
famili
member
iii
research
inform
provis
factor
influenc
decis
research
participantsfamili
member
iv
challeng
face
irb
factor
might
influenc
review
oversight
set
v
dynam
research
collabor
vi
multipl
commit
investig
staff
due
exist
emerg
workload
vii
role
media
wider
societi
rapidli
evolv
epidem
issu
gener
concern
other
uniqu
rapidli
evolv
epidem
stress
consider
address
effect
next
major
epidem
pandem
